PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 1, 1993Journal of Clinical Oncology225 citations

Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

View Full Paper
DTD G TubergenThe University of Texas MD Anderson Cancer CenterGGGerald S. GilchristUniversity of VermontRORichard T. O’BrienUnited States Naval Academy

Key Points

  • The study aims to assess the effectiveness of delayed intensification in improving outcomes for children with acute lymphoblastic leukemia (ALL) and intermediate-risk features.
  • Phase III trial conducted by the Children's Cancer Group
  • Substitution of maintenance intrathecal methotrexate for cranial radiation therapy in presymptomatic patients
  • Participants included children with intermediate-risk characteristics under 10 years old.
  • Delayed intensification improved the event-free survival rate in children with ALL.
  • Alternative CNS therapy using maintenance IT MTX was found to be safely substituted for CXRT.

Abstract

Delint improves the EFS rate of children with ALL and intermediate presenting features. Maintenance IT MTX can be safely substituted for CXRT for presymptomatic CNS therapy in children with intermediate-risk characteristics less than 10 years of age.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tubergen et al. (1993) studied this question.

synapsesocial.com/papers/69d819f9b5518339b2ae2ccfhttps://doi.org/10.1200/jco.1993.11.3.527
Ask AI
Helpful
Bookmark
Share
View Full Paper